Phillip D Toth MD FACP
Midwest Institute For Clinical Research/owner
Join to View Full Profile
8803 N Meridian StSuite 200Indianapolis, IN 46260
Phone+1 317-705-7050
Fax+1 317-705-7051
Dr. Toth is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- I have the only, independent, dedicated, full-time, clinical trial site in the Indianapolis metropolitan area. Since 1988, I have participated in over 540 clinical trials in the cardio-metabolic area of drug development including hyperlipidemia, hypertension, diabetes, obesity, NAFLD, and atherosclerotic cardiovascular disease.
Education & Training
Indiana University School of MedicineResidency, Internal Medicine, 1978 - 1980- Indiana University School of Medicine/Methodist HospitalInternship, Transitional Year, 1977 - 1978
Washington University in St. Louis School of MedicineClass of 1977
Certifications & Licensure
IN State Medical License 1978 - 2025
American Board of Internal Medicine Internal Medicine
Clinical Trials
- Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus Start of enrollment: 2010 Jun 18
- A Study of LY2623091 in Participants With High Blood Pressure Start of enrollment: 2014 Aug 01
- A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol Start of enrollment: 2014 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- 524 citationsA 52-Week Placebo-Controlled Trial of Evolocumab in HyperlipidemiaDirk J. Blom, Tomas Hala, Michael A. Bolognese, Michael J. Lillestol, Phillip D. Toth
The New England Journal of Medicine. 2014-05-07 - 164 citationsLong-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia.Moti L. Kashyap, Mark E. McGovern, Kathleen Berra, John R. Guyton, Peter O. Kwiterovich
The American Journal of Cardiology. 2002-03-15 - 97 citationsEffectiveness of Colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia : A 24-week randomized controlled trialWilliam Insull, Phillip D Toth, William S. Mullican, Donald B. Hunninghake, Steven K. Burke
Mayo Clinic Proceedings. 2001-10-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
